Plasmanate Market Report 2026

Plasmanate Market Overview

• The Plasmanate market growth in the historic period has been driven by expansion of surgical procedures requiring volume replacement, availability of plasma fractionation technologies • Market expansion is supported by increasing demand for safer plasma-derived products, rising investments in plasma collection infrastructure • Growth Driver: Rising Trauma Cases Boost Demand For Plasmanate In Critical Care And Recovery • North America was the largest region in 2025.

What Is Covered Under Plasmanate Market?

Plasmanate is a plasma protein fraction derived from human blood, primarily composed of albumin, used as a volume expander in medical settings. It is often administered to treat hypovolemia (low blood volume) due to surgery, trauma, or burns. It is pasteurized to reduce the risk of viral transmission and ensure safety. The main formulations for plasmanate are liquid formulations and lyophilized formulations. Liquid formulations refer to plasmanate products in liquid form that can be administered directly to patients to restore fluids and proteins. These are commonly used in emergency and hospital settings for quick and effective treatment. The liquid formulation allows for rapid infusion and immediate therapeutic effects. Clinical indications for plasmanate include hypovolemia, burns, shock, hypoproteinemia, and surgical procedures. It is distributed through various channels, such as online pharmacies and wholesale distributors, and is widely utilized by hospitals and clinical research laboratories.

What Is The Plasmanate Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for safer plasma-derived products, rising investments in plasma collection infrastructure, expansion of emergency and trauma care services, growing focus on protein-based therapeutics, advancements in plasma processing technologies. Major trends in the forecast period include increasing use of plasma protein volume expanders, rising demand for blood-derived therapeutics, growing emphasis on safe and pasteurized plasma products, expansion of critical care applications, enhanced focus on supply chain traceability.

Global Plasmanate Market Segmentation

1) By Formulation: Liquid Formulations, Lyophilized Formulations 2) By Clinical Indication: Hypovolemia, Burns, Shock, Hypoproteinemia, Surgical Procedures 3) By Distribution Channel: Online Pharmacies, Wholesale Distributors 4) By End User: Hospitals, Clinical Research Laboratories

What Are The Drivers Of The Plasmanate Market?

The rising incidence of trauma cases is expected to propel the growth of the plasmanate market going forward. Trauma cases involve serious physical or psychological injuries from external forces or distressing events, requiring immediate medical treatment, surgery, rehabilitation, and psychological support for recovery. The increase in trauma cases is due to higher accident rates, urbanization leading to more exposure to hazardous situations, and lifestyle changes such as increased risk-taking behavior and substance abuse. Trauma patients may suffer from hypovolemic shock (due to significant blood loss), where plasma transfusion is crucial for restoring circulating blood volume and maintaining blood pressure. For instance, in 2025, according to the Wisconsin Department of Health Services (DHS), a U.S.-based state government health agency reported that Wisconsin trauma cases rose about 5.6% from 2023 to 2024. Therefore, the rising incidence of trauma cases is driving the growth of the plasmanate industry. The increasing prevalence of autoimmune diseases is projected to drive the growth of the plasmanate market going forward. Autoimmune diseases occur when the body's immune system mistakenly attacks its healthy cells, tissues, and organs, perceiving them as foreign invaders. The rising prevalence of autoimmune diseases is attributed to a combination of factors, including increased awareness and diagnosis, genetic predispositions, and environmental influences such as pollutants, dietary changes, and lifestyle factors. Plasmanate is used in autoimmune diseases to restore plasma volume and stabilize hemodynamics, supporting patients during immune-mediated crises. For instance, in July 2024, according to the National Health Service (NHS) England, a UK-based government department, multiple sclerosis affects over 150,000 people in the UK, with more than 120,000 in England, and is more prevalent in women. Approximately 135 new diagnoses are made weekly, highlighting its significant impact on the population. Therefore, the increasing prevalence of autoimmune diseases is fueling plasmanate industry growth. The growing prevalence of chronic illnesses is anticipated to expand the plasmanate market in the coming years. Chronic illnesses are long-lasting health conditions that persist for a year or more and typically require ongoing medical attention or limit activities of daily living. The rising prevalence of chronic illnesses is driven by factors such as increasing exposure to risk factors such as obesity, high blood pressure, and unhealthy lifestyles, along with aging populations and environmental influences that contribute to the development of non-communicable diseases. Plasmanate is used in chronic diseases to restore plasma volume and treat hypoproteinemia in conditions such as liver disease, severe burns, or nephrotic syndrome. For instance, in 2025, according to the Northern Arizona Medical Group, a US-based healthcare provider, nearly three-quarters of the world’s population is projected to live with at least one chronic illness, and the prevalence of chronic illnesses continues to increase notably. In the United States, in 2023, about 76.4% of adults reported having at least one chronic condition, and 51.4% had two or more. Therefore, the growing prevalence of chronic illnesses is fueling the growth of the plasmanate industry.

Key Players In The Global Plasmanate Market

Major companies operating in the plasmanate market are Grifols Therapeutics LLC

Regional Insights

North America was the largest region in the plasmanate market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Plasmanate Market?

The plasmanate market consists of sales of plasmanate 5% infusion, and plasmanate 5% injection 250ml. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plasmanate Market Report 2026?

The plasmanate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasmanate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.